This clinical trial is focused on studying the treatment of HIV infection using a medication called Doravirine/Islatravir (also known by the code name MK-8591A). The medication is taken as a film-coated tablet and is designed to be taken once daily. The purpose of the study is to evaluate the safety and tolerability of this treatment in participants who have previously received it in earlier clinical studies.
Participants in this study will continue to take the Doravirine/Islatravir tablet as part of their treatment for HIV infection. The study will monitor participants over a period to gather information on any serious adverse events or reasons for discontinuing the treatment due to adverse effects. This information will help researchers understand how well the treatment is tolerated by those who have already been using it.
The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. This trial is a continuation for those who have already been part of previous studies involving Doravirine/Islatravir, allowing them to continue their treatment while contributing to the collection of important safety data.



France
Italy